Cite
HARVARD Citation
Devillier, R. et al. (2016). Combination therapy with ruxolitinib plus intensive treatment strategy is feasible in patients with blast‐phase myeloproliferative neoplasms. British journal of haematology. pp. 628-630. [Online].